Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Tobacco/Nicotine Use Disorder (TUD)

DMT for Tobacco/Nicotine Use Disorder (TUD)

5 papers and 1 clinical trial exploring dmt as a treatment for tobacco/nicotine use disorder (tud).

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
Indication1.3 billion smokers worldwide.

Tobacco/Nicotine Use Disorder (TUD)

Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.

Full Tobacco/Nicotine Use Disorder (TUD) profile

Academic Research

5 papers
Open Accessindividual

Health-related behavioral changes following the use of psychedelics in naturalistic settings

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

Published
August 1, 2025
Journal
Preventative Medicine Reports
Authors
Teixeira, P. J., Jain, R., Penn, A. D., Cole, S. P., Jain, S., Moller, A. C., Amaro, H., Raison, C.
Paywallindividual

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Using nationally representative US survey data (NSDUH 2005–2014), lifetime use of classic psychedelics was associated with lower odds of past‑year hypertension after adjustment (adjusted odds ratio 0.86, 95% CI 0.81–0.91), an effect driven specifically by lifetime tryptamine use (aOR 0.80, 95% CI 0.73–0.89). These cross‑sectional findings suggest a potential protective link but cannot establish causality; randomised controlled trials are needed to probe mechanisms and causal effects on blood pressure.

Published
May 1, 2021
Journal
Hypertension
Authors
Simonsson, O., Hendricks, P. S., Carhart-Harris, R., Kettner, H., Osika, W.
Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published
April 1, 2016
Journal
Pharmacological Reviews
Authors
Nichols, D. E.
Open Accessindividual

Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample

In a 2012 Global Drug Survey of 22,289 respondents lifetime DMT use was 8.9% (past-year 5.0%), and among 472 recent first-time DMT users the drug—most often smoked—produced a short‑lived, intense psychedelic experience with relatively few negative effects or “come down.” The profile suggests high desirability and potential abuse liability, which may be offset by a low urge to re‑use, while a larger proportion of new users relative to psilocybin, LSD and ketamine points to possible rising popularity.

Published
November 27, 2013
Journal
Journal of Psychopharmacology
Authors
Winstock, A. R., Kaar, S., Borschmann, R.
Paywallindividual

Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreational users

This survey study (n=121) found that smoking was the most common way of using DMT (98% vs 30% in ayahuasca) amongst Australian users. A general interest in psychedelics and DMT specifically were the main reasons for using it.

Published
September 1, 2010
Journal
Drug and Alcohol Dependence
Authors
Cakic, V., Potkonyak, J., Marshall, A.

Clinical Trials

1 trial
CompletedPhase I

A study on the safety and effects of the drug DMT in healthy smoking individuals

Randomised, double-blind, placebo-controlled Phase I single ascending dose IV infusion study (n=50) assessing safety, PK/PD and tolerability of target-controlled DMT infusion in healthy smokers.

Started
January 8, 2021
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
ISRCTN11577984

Explore further

Search all DMT papers Search all Tobacco/Nicotine Use Disorder (TUD) trials Full DMT profile Full Tobacco/Nicotine Use Disorder (TUD) profile